Generic Name and Formulations:
Von Willebrand Factor/Factor VIII Complex (human); 500 IU VWF:RCo and 500 IU FVIII activities per 5mL; 1000 IU VWF:RCo and 1000 IU FVIII activities per 10mL; pwd for IV injection after reconstitution; preservative-free; solvent-detergent treated.

Company:
Octapharma
Indications for WILATE:
On-demand treatment and control of bleeding episodes in patients with von Willebrand disease (VWD). Perioperative management of bleeding in patients with VWD.

Limitations Of use:
Not for treatment of hemophilia A.

Adults and Children:
<5yrs: contact manufacturer. Give by IV injection at 2–4mL/min. ≥5yrs: Minor bleed: 20–40 IU/kg once, then 20–30 IU/kg every 12–24 hours as needed. Major bleed: 40–60 IU/kg once, then 20–40 IU/kg every 12–24 hours as needed. Surgery (give loading dose within 3hrs before); Minor: 30–60 IU/kg once, then 15–30 IU/kg every 12–24 hours; Major: 40–60 IU/kg once, then 20–40 IU/kg every 12–24 hours. Monitor and adjust according to VWF:RCo and FVIII activity, and location of bleed; usual treatment duration is 3 days (minor hemorrhage, minor surgery), 5–7 days (major hemorrhage), or ≥6 days (major surgery). See full labeling.

Warnings/Precautions:
Treatment should be supervised by physician trained in coagulopathies. Risk of thrombotic events with sustained excessive FVIII levels; monitor. Ineffectiveness may indicate antibody formation; discontinue if confirmed. Risk of transmission of blood-borne diseases; consider vaccination against hepatitis A and B. Monitor pulse during injection; slow or stop infusion if marked increase in heart rate occurs. Pregnancy. Nursing mothers.

Pharmacological Class:
Coagulation factor complex.

Adverse Reactions:
Urticaria, dizziness, hypersensitivity reactions; antibody formation.

How Supplied:
Kit—1 (w. diluent, supplies)